Evidence map›Paper›PMID 38883925›Full record

ArticlePreventive medicine reports2024

Clinician-perceived barriers to cervical cancer screening before and during the COVID-19 pandemic at three US healthcare systems.

Veronica M Boratyn, Gaia Pocobelli, Steven J Atlas, Cheryl R Clark, Sarah Feldman, Gina Kruse, Anne Marie McCarthy, Meghan Rieu-Werden, Michelle I Silver, Noel O Santini and 2 more

Abstract read
In one paragraph

Article in Preventive medicine reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Veronica M BoratynDivision of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Gaia PocobelliKaiser Permanente Washington Health Research Institute, Seattle, Washington, United States.
Steven J AtlasDivision of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Cheryl R ClarkDivision of General Internal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Sarah FeldmanDepartment of Obstetrics Gynecology & Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Gina KruseDivision of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Anne Marie McCarthyDepartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.
Meghan Rieu-WerdenDivision of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Michelle I SilverDepartment of Surgery, Washington University School of Medicine, St. Louis, MO, United States.
Noel O SantiniParkland Health, Dallas, TX, United States.
Jasmin A TiroDivision of General Internal Medicine, UT Southwestern Medical Center, Dallas, TX, United States.
Jennifer S HaasDivision of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The COVID-19 pandemic posed serious challenges to cancer screening delivery, including cervical cancer. While the impact of the pandemic on deferred screening has been documented, less is known about how clinicians experienced barriers to screening delivery, and, in particular, the role of pre-pandemic barriers to changes reported during the pandemic. Methods: Survey of clinicians who performed ≥ 10 cervical cancer screening tests in 2019 from Mass General Brigham, Kaiser Permanente Washington, and Parkland Health, the healthcare systems participating in the Population-based Research to Optimize the Screening Process (PROSPR II) consortium (administered 10/2020-12/2020, response rate 53.7 %). Results: Prior to the pandemic, clinicians commonly noted barriers to the delivery of cervical cancer screening including lack of staff support (57.6%), interpreters (32.5%), resources to support patients with social barriers to care (61.3%), and discrimination or bias in interactions between staff and patients (31.2%). Clinicians who reported experiencing a given barrier to care before the pandemic were more likely than those who did not experience one to report worsening during the pandemic: lack of staff support (odds ratio 4.70, 95% confidence interval 2.94-7.52); lack of interpreters (8.23, 4.46-15.18); lack of resources to support patients in overcoming social barriers (7.65, 4.41-13.27); and discrimination or bias (6.73, 3.03-14.97). Conclusions: Clinicians from three health systems who deliver cervical cancer screening commonly reported barriers to care. Barriers prior to the pandemic were associated with worsening of barriers during the pandemic. Addressing barriers to cervical cancer screening may promote resilience of care delivery during the next public health emergency.

Indexed as

Barriers to careCancer screeningPublic healthSurvey

Identifiers

PMID38883925
PMCPMC11180331

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.